UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES
EXCHANGE ACT OF 1934
Dated
February,
2016
Commission
File Number 001-36421
AURINIA PHARMACEUTICALS INC.
(Exact
name of Registrant as specified in its charter)
N/A
(Translation of Registrant’s Name)
#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250)
708-4272
(Address and telephone number of registrant’s
principle executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ⃞ Form 40-F ⊠
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): ⃞
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ⃞
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ⃞ No ⊠
If "Yes" is
marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: |
February 4, 2016 |
|||
Aurinia Pharmaceuticals Inc. |
||||
|
||||
|
|
By: |
/s/ Michael R. Martin |
|
|
Name: |
Michael R. Martin |
||
|
|
Title: |
Chief Operating Officer |
EXHIBIT INDEX
Exhibit |
Description of Exhibit |
|
99.1 |
News Release – Aurinia Pharmaceuticals to Attend Two Upcoming Investor Conferences |
3
Exhibit 99.1
Aurinia Pharmaceuticals to Attend Two Upcoming Investor Conferences
VICTORIA, British Columbia--(BUSINESS WIRE)--February 4, 2016--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH / TSX:AUP) today announced that its Chief Operating Officer Michael R. Martin will attend two upcoming investor conferences. A general corporate overview will be provided in presentation format during the Source Capital 2016 Disruptive Growth & Healthcare Conference on February 10th, 2016, while a fireside chat & discussion will occur at the 5th Annual Leerink Global Healthcare Conference on February 11th, 2016. Times for these presentations and discussions are specified as follows:
Aurinia Source Capital Presentation Details
Date: Wednesday, February 10th, 2016
Time: 4:30 p.m.
Eastern Standard Time
Location: New York, NY, Convene Conference
Centre – Murray Hill Hub
Webcast: http://wsw.com/webcast/sourcecap1/auph
Aurinia 5th Annual Leerink Global Healthcare Conference Fireside Chat Details
Date: Thursday, February 11th, 2016
Time: 1:50 p.m.
Eastern Standard Time
Location: New York, NY, Waldorf Astoria Hotel,
South Terrace Room
Webcast: http://wsw.com/webcast/leerink26/auph
Live webcasts of the presentations and discussions will be available at the above coordinates, archived webcasts and materials will also be available on the Company’s website at www.auriniapharma.com
About Aurinia
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently collecting data in its 265 patient Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.
Visit www.auriniapharma.com for more information.
CONTACT:
Company Contact:
Stephen Zaruby, 250-708-4293
President
& Chief Executive Officer
szaruby@auriniapharma.com
or
Investor
& Media Contact:
Michael R. Martin, 250-708-4272
Chief
Operating Officer
mmartin@auriniapharma.com
or
Renmark
Financial Communications Inc.
Barry Mire, 416-644-2020
bmire@renmarkfinancial.com
or
Laura
Welsh, 514-939-3989
lwelsh@renmarkfinancial.com